You are viewing a preview of...

COVID-19 Diagnosis, Prognosis, and Treatment

Metabolite and protein COVID-19 biomarkers accurately diagnose, predict disease outcome, and identify promising therapeutic targets

Background

In early 2020 Lawson researchers were quick to initiate and were the first in the world to publish the results of a series of multi‑pronged studies on COVID‑19 with the aim of characterizing the patient immune and pathophysiological response to the virus, and to identify specific biomarkers useful for confirming diagnosis, evaluating prognosis and to serve as evidence‑based therapeutic targets for clinical trials. Using the state of the art metabolomic and proteomic assays combined with advanced mathematical techniques, the team determined/compared the metabolomes and proteomes between age and sex matched COVID19 positive (+) ICU patients and either healthy control subjects or COVID19 negative (–) ICU patients. Specific metabolite and protein biomarkers were determined that 1) accurately differentiated COVID19+ from

Log in or create a free account to continue reading